Impaired hemostatic activity of healthy transfused platelets in inherited and acquired platelet disorders: Mechanisms and implications
- 11 December 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (522)
Abstract
Platelet transfusions can fail to prevent bleeding in patients with inherited platelet function disorders (IPDs), such as Glanzmann’s thrombasthenia (GT; integrin αIIbβ3 dysfunction), Bernard-Soulier syndrome [BSS; glycoprotein (GP) Ib/V/IX dysfunction], and the more recently identified nonsyndromic RASGRP2 variants. Here, we used IPD mouse models and real-time imaging of hemostatic plug formation to investigate whether dysfunctional platelets impair the hemostatic function of healthy donor [wild-type (WT)] platelets. In Rasgrp2−/− mice or mice with platelet-specific deficiency in the integrin adaptor protein TALIN1 (“GT-like”), WT platelet transfusion was ineffective unless the ratio between mutant and WT platelets was ~2:1. In contrast, thrombocytopenic mice or mice lacking the extracellular domain of GPIbα (“BSS-like”) required very few transfused WT platelets to normalize hemostasis. Both Rasgrp2−/− and GT-like, but not BSS-like, platelets effectively localized to the injury site. Mechanistic studies identified at least two mechanisms of interference by dysfunctional platelets in IPDs: (i) delayed adhesion of WT donor platelets due to reduced access to GPIbα ligands exposed at sites of vascular injury and (ii) impaired consolidation of the hemostatic plug. We also investigated the hemostatic activity of transfused platelets in the setting of dual antiplatelet therapy (DAPT), an acquired platelet function disorder (APD). “DAPT” platelets did not prolong the time to initial hemostasis, but plugs were unstable and frequent rebleeding was observed. Thus, we propose that the endogenous platelet count and the ratio of transfused versus endogenous platelets should be considered when treating select IPD and APD patients with platelet transfusions.Keywords
Funding Information
- National Heart, Lung, and Blood Institute
This publication has 73 references indexed in Scilit:
- Platelet ITAM signaling is critical for vascular integrity in inflammationJournal of Clinical Investigation, 2013
- Relative contributions of stromal interaction molecule 1 and CalDAG‐GEFI to calcium‐dependent platelet activation and thrombosisJournal of Thrombosis and Haemostasis, 2011
- CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin αIIbβ3 in plateletsBlood, 2008
- Talin is required for integrin-mediated platelet function in hemostasis and thrombosisJournal of Experimental Medicine, 2007
- Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type IIIJournal of Clinical Investigation, 2007
- The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosisProceedings of the National Academy of Sciences, 2006
- Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndromeBlood, 2002
- Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonistsThe American Journal of Cardiology, 1991
- Hemostasis in Glanzmannʼs Thrombasthenia (GT)Journal of Pediatric Hematology/Oncology, 1991
- The Effect of Storage on Adhesion and Aggregation of Platelets1Vox Sanguinis, 1970